Cargando…
Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma
Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%–10% of HL patients are refractory...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188182/ https://www.ncbi.nlm.nih.gov/pubmed/30349293 http://dx.doi.org/10.2147/OTT.S175016 |
_version_ | 1783363176125956096 |
---|---|
author | Garcia-Recio, Marta Martinez-Serra, Jordi Mestre, Francesc Bento, Leyre Gines, Jordi Ramos, Rafael Daumal, Jaime López, Paloma Sampol, Antonia Gutierrez, Antonio |
author_facet | Garcia-Recio, Marta Martinez-Serra, Jordi Mestre, Francesc Bento, Leyre Gines, Jordi Ramos, Rafael Daumal, Jaime López, Paloma Sampol, Antonia Gutierrez, Antonio |
author_sort | Garcia-Recio, Marta |
collection | PubMed |
description | Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%–10% of HL patients are refractory to initial treatment and 10%–30% of patients will eventually relapse after an initial CR. The treatment recommendation for primary refractory or relapsed HL patients is salvage therapy followed by high-dose chemotherapy and autologous stem cell transplantation. Following this approach, a significant part will still relapse at any moment. Thus, further research and new drugs or combinations are required. Overexpression of COX-2 has been associated with poor prognosis in relapse/refractory HL patients, so it could be a potential therapeutic target in HL. For this purpose, several drugs may have a role: specific COX-2 inhibitors such as celecoxib or other anti-inflammatory drugs such as lenalidomide may further inhibit lipopolysaccharide-mediated induction of COX-2. Moreover, lenalidomide and COX-2 inhibitors (celecoxib) have been tested in solid tumors with encouraging results. We present a case of a young female diagnosed with a heavily pretreated HL nodular sclerosis subtype who, after failing six treatment lines, only achieved clinical and radiological CR after six cycles of lenalidomide/celecoxib that resulted in an event-free survival of 22 months. We explain the rationale of using this chemotherapy regimen and our patient follow-up. |
format | Online Article Text |
id | pubmed-6188182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61881822018-10-22 Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma Garcia-Recio, Marta Martinez-Serra, Jordi Mestre, Francesc Bento, Leyre Gines, Jordi Ramos, Rafael Daumal, Jaime López, Paloma Sampol, Antonia Gutierrez, Antonio Onco Targets Ther Case Report Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%–10% of HL patients are refractory to initial treatment and 10%–30% of patients will eventually relapse after an initial CR. The treatment recommendation for primary refractory or relapsed HL patients is salvage therapy followed by high-dose chemotherapy and autologous stem cell transplantation. Following this approach, a significant part will still relapse at any moment. Thus, further research and new drugs or combinations are required. Overexpression of COX-2 has been associated with poor prognosis in relapse/refractory HL patients, so it could be a potential therapeutic target in HL. For this purpose, several drugs may have a role: specific COX-2 inhibitors such as celecoxib or other anti-inflammatory drugs such as lenalidomide may further inhibit lipopolysaccharide-mediated induction of COX-2. Moreover, lenalidomide and COX-2 inhibitors (celecoxib) have been tested in solid tumors with encouraging results. We present a case of a young female diagnosed with a heavily pretreated HL nodular sclerosis subtype who, after failing six treatment lines, only achieved clinical and radiological CR after six cycles of lenalidomide/celecoxib that resulted in an event-free survival of 22 months. We explain the rationale of using this chemotherapy regimen and our patient follow-up. Dove Medical Press 2018-10-08 /pmc/articles/PMC6188182/ /pubmed/30349293 http://dx.doi.org/10.2147/OTT.S175016 Text en © 2018 Garcia-Recio et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Report Garcia-Recio, Marta Martinez-Serra, Jordi Mestre, Francesc Bento, Leyre Gines, Jordi Ramos, Rafael Daumal, Jaime López, Paloma Sampol, Antonia Gutierrez, Antonio Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma |
title | Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma |
title_full | Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma |
title_fullStr | Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma |
title_full_unstemmed | Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma |
title_short | Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma |
title_sort | complete response associated with lenalidomide and celecoxib in a case of primary refractory hodgkin lymphoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188182/ https://www.ncbi.nlm.nih.gov/pubmed/30349293 http://dx.doi.org/10.2147/OTT.S175016 |
work_keys_str_mv | AT garciareciomarta completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT martinezserrajordi completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT mestrefrancesc completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT bentoleyre completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT ginesjordi completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT ramosrafael completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT daumaljaime completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT lopezpaloma completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT sampolantonia completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma AT gutierrezantonio completeresponseassociatedwithlenalidomideandcelecoxibinacaseofprimaryrefractoryhodgkinlymphoma |